Crescent Biopharma (NASDAQ:CBIO - Get Free Report) was upgraded by equities researchers at Wall Street Zen to a "sell" rating in a report released on Saturday.
Other analysts have also recently issued reports about the stock. Lifesci Capital raised shares of Crescent Biopharma to a "strong-buy" rating and set a $22.00 target price on the stock in a report on Wednesday, June 18th. Stifel Nicolaus initiated coverage on shares of Crescent Biopharma in a report on Wednesday, June 25th. They set a "buy" rating and a $28.00 target price on the stock. Finally, TD Cowen raised shares of Crescent Biopharma to a "strong-buy" rating in a report on Friday, June 20th.
Check Out Our Latest Stock Report on CBIO
Crescent Biopharma Stock Performance
Shares of NASDAQ:CBIO opened at $12.96 on Friday. The firm has a market cap of $253.37 million, a price-to-earnings ratio of -0.28 and a beta of 1.52. Crescent Biopharma has a 1-year low of $11.06 and a 1-year high of $63.00.
Crescent Biopharma Company Profile
(
Get Free Report)
Crescent Biopharma, Inc operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Crescent Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Crescent Biopharma wasn't on the list.
While Crescent Biopharma currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
